Medexus Pharmaceuticals Inc. (MDP) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Medexis Fiscal Second Quarter 2024 Earnings Call. At this time, all participants are on a listen-only mode and a question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note, this conference is being recorded. I will now turn the conference over to your host, Magda Gardner of Investor Relations. Magda, you may begin. Thank you, and good morning, everyone. Welcome to the Medexus Pharmaceuticals second fiscal quarter 2024 earnings call. On the call this morning are Ken D'Entremont, Chief Executive Officer, and Marcel Conrad, Chief Financial Officer. If you have any questions after the conference call or would like more information about the company, please contact Adelaide Capital at 416-206-8869. I would like to remind everyone that this discussion will include forward-looking information as defined in securities law. Actual results may differ materially from historical results or results anticipated by the forward-looking information. In addition, this discussion will also include non-GAAP measures, such as adjusted debt income and loss and adjusted EBITDA, which do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. For more information about forward-looking information and non-GAAP measures, including reconciliations to net income and loss. Please refer to the company's MD&A, which along with the financial statements is available on the company's website at www.medexus.com and on CDAR Plus at www.cdarplus.ca. As a reminder, Medexus reports on a March 31st fiscal year basis. Medexus reports financial results in U.S. dollars. I wo...